Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/25/2026

1. AKAM
2. COST
3. SPY
4. META
5. ZS
6. ULS
7. CRL
8. NVDA
9. PRME
10. DRI

Go back to Merck Initiates Phase 3 Study Evaluating Dengue Vaccine Candidate
Merck & Co. (NYSE: MRK) Delayed: 147.98 --0 (-0%)
Previous Close $147.98    52 Week High $65.46 
Open $147.98    52 Week Low $47.97 
Day High $147.98    P/E 100.67 
Day Low $147.98    EPS $1.47 
Volume 9,526